Dengue vaccine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dengue vaccine" in English language version.

refsWebsite

Global rank English rank

24nih.gov

4^th place

15doi.org

2^nd place

7web.archive.org

1^st place

6europa.eu

68^th place

117^th place

5handle.net

102^nd place

76^th place

5semanticscholar.org

11^th place

8^th place

4fiercepharma.com

low place

8,921^st place

4reuters.com

49^th place

47^th place

3tga.gov.au

3,984^th place

2,622^nd place

3takeda.com

low place

2fda.gov

447^th place

338^th place

2umn.edu

1,266^th place

860^th place

2who.int

195^th place

302^nd place

2mercopress.com

6,267^th place

4,336^th place

1cnnbrasil.com.br

3,706^th place

7,768^th place

1medicines.org.uk

3,823^rd place

2,387^th place

1drugs.com

399^th place

333^rd place

1gmanetwork.com

824^th place

488^th place

1statnews.com

8,771^st place

5,253^rd place

1scientificamerican.com

896^th place

674^th place

1cnn.com

28^th place

26^th place

1tempo.co

1,326^th place

2,778^th place

1archive.today

14^th place

1sciencenewsline.com

low place

1uftm.edu.br

low place

1evaluate.com

low place

1merck.com

6,464^th place

5,671^st place

1medigen.com.tw

low place

1indiatimes.com

17^th place

15^th place

1denguevaccines.org

low place

1bloomberg.com

99^th place

77^th place

archive.today

"The Lancet: World's Most Advanced Dengue Vaccine Candidate Shows Promise in Phase 3 Trial". Science Newsline medicine. 10 July 2014. Archived from the original on 15 July 2014. Retrieved 13 July 2014.

bloomberg.com

"Takeda UK Ltd. announces MHRA approval for dengue virus vaccine candidate Qdenga". Bloomberg.com (Press release). 6 February 2023. Retrieved 9 February 2023.

cnn.com

edition.cnn.com

East S (6 April 2016). "World's first dengue fever vaccine launched in the Philippines". CNN. Retrieved 17 October 2016.

cnnbrasil.com.br

"Vacina contra a dengue: aplicação começa nesta semana em clínicas particulares" [Dengue vaccine: administration starts this week in private clinics]. CNN Brazil (in Portuguese). 26 June 2023. Retrieved 29 June 2023.

denguevaccines.org

"Vaccine Development. Dengue Vaccine Initiative". Archived from the original on 21 August 2019. Retrieved 31 July 2015.

doi.org

McArthur MA, Sztein MB, Edelman R (August 2013). "Dengue vaccines: recent developments, ongoing challenges and current candidates". Expert Review of Vaccines. 12 (8): 933–953. doi:10.1586/14760584.2013.815412. PMC 3773977. PMID 23984962.
Freedman DO (November 2023). "A new dengue vaccine (TAK-003) now WHO recommended in endemic areas; what about travellers?". J Travel Med. 30 (7): 1–3. doi:10.1093/jtm/taad132. PMID 37847608.
Redoni M, Yacoub S, Rivino L, Giacobbe DR, Luzzati R, Di Bella S (July 2020). "Dengue: Status of current and under-development vaccines". Reviews in Medical Virology. 30 (4): e2101. doi:10.1002/rmv.2101. hdl:1983/6d38d9b6-8e1b-4a84-85e3-edab4fc41957. PMID 32101634. S2CID 211536962.
Thisyakorn U, Thisyakorn C (January 2014). "Latest developments and future directions in dengue vaccines". Therapeutic Advances in Vaccines. 2 (1): 3–9. doi:10.1177/2051013613507862. PMC 3991153. PMID 24757522.
Yauch LE, Shresta S (2014). "Dengue virus vaccine development". Advances in Virus Research. 88: 315–372. doi:10.1016/B978-0-12-800098-4.00007-6. ISBN 9780128000984. PMID 24373316.
Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. (October 2014). "Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial". Lancet. 384 (9951): 1358–1365. doi:10.1016/s0140-6736(14)61060-6. PMID 25018116. S2CID 42841451.
Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al. (January 2015). "Efficacy of a tetravalent dengue vaccine in children in Latin America". The New England Journal of Medicine. 372 (2): 113–123. doi:10.1056/nejmoa1411037. PMID 25365753. S2CID 2839926.
Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. (September 2015). "Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease". The New England Journal of Medicine. 373 (13): 1195–1206. doi:10.1056/NEJMoa1506223. PMID 26214039.
Osorio JE, Huang CY, Kinney RM, Stinchcomb DT (September 2011). "Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever". Vaccine. 29 (42): 7251–7260. doi:10.1016/j.vaccine.2011.07.020. PMC 4592106. PMID 21777638.
Schwartz LM, Halloran ME, Durbin AP, Longini IM (June 2015). "The dengue vaccine pipeline: Implications for the future of dengue control". Vaccine. 33 (29): 3293–3298. doi:10.1016/j.vaccine.2015.05.010. PMC 4470297. PMID 25989449.
Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, et al. (November 2019). "Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents". The New England Journal of Medicine. 381 (21): 2009–2019. doi:10.1056/NEJMoa1903869. PMID 31693803. S2CID 207952783.
Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, et al. (March 2016). "The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model". Science Translational Medicine. 8 (330): 330ra36. doi:10.1126/scitranslmed.aaf1517. PMID 27089205. S2CID 206690615.
Whitehead SS (2016). "Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?". Expert Review of Vaccines. 15 (4): 509–517. doi:10.1586/14760584.2016.1115727. PMC 4956407. PMID 26559731.
Khetarpal N, Khanna I (2016). "Dengue Fever: Causes, Complications, and Vaccine Strategies". Journal of Immunology Research. 2016: 6803098. doi:10.1155/2016/6803098. PMC 4971387. PMID 27525287.
Manoff SB, Sausser M, Falk Russell A, Martin J, Radley D, Hyatt D, et al. (3 June 2019). "Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults". Human Vaccines & Immunotherapeutics. 15 (9): 2195–2204. doi:10.1080/21645515.2018.1546523. PMC 6773383. PMID 30427741.

drugs.com

"Dengue Vaccine Live Monograph for Professionals". Drugs.com. 23 August 2023. Retrieved 14 November 2019.

europa.eu

ema.europa.eu

"Dengvaxia EPAR". European Medicines Agency (EMA). 23 October 2019. Archived from the original on 6 December 2019. Retrieved 6 December 2019.
"Qdenga EPAR". European Medicines Agency (EMA). 16 December 2022. Retrieved 28 December 2022.
"New vaccine to protect people in the EU and worldwide against dengue". European Medicines Agency (EMA) (Press release). 14 October 2022. Retrieved 14 October 2022.
"Qdenga: Pending EC decision". European Medicines Agency (EMA). 14 October 2022. Archived from the original on 14 October 2022. Retrieved 14 October 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"New vaccine to protect people in the EU and worldwide against dengue". European Medicines Agency (EMA) (Press release). 14 October 2022. Retrieved 14 October 2022.

ec.europa.eu

"Qdenga Product information". Union Register of medicinal products. Retrieved 3 March 2023.

evaluate.com

Armstrong M (7 November 2019). "Takeda's dengue data spell more bad news for Sanofi". Evaluate Ltd. Retrieved 11 November 2019.

fda.gov

"First FDA-approved vaccine for the prevention of dengue disease in endemic regions". U.S. Food and Drug Administration (FDA) (Press release). 1 May 2019. Archived from the original on 6 December 2019. Retrieved 14 November 2019. This article incorporates text from this source, which is in the public domain.
"Dengvaxia". U.S. Food and Drug Administration (FDA). 21 May 2019. STN 125682. Archived from the original on 6 December 2019. Retrieved 6 December 2019. This article incorporates text from this source, which is in the public domain.

fiercepharma.com

Becker Z (22 August 2022). "Takeda's dengue fever vaccine picks up first global nod in Indonesia". Fierce Pharma. Retrieved 25 November 2022.
Palmer, Eric (9 December 2015). "Sanofi gets first approval for long-anticipated vaccine against dengue fever". FiercePharma. Archived from the original on 16 March 2016. Retrieved 10 December 2015.
Angus L (11 July 2023). "UPDATED: Takeda yanks FDA filing for dengue vaccine, citing data disagreement with regulator". Fierce Pharma. Retrieved 14 July 2023.
Becker Z (21 March 2023). "As approvals roll in, Takeda details pricing strategy for dengue vaccine launch". Fierce Pharma. Retrieved 14 July 2023.

gmanetwork.com

Lopez V (4 December 2017). "DOJ orders NBI to investigate P3.5-B dengue vaccine scandal". STAT. Retrieved 14 December 2017.

handle.net

hdl.handle.net

World Health Organization (24 November 2023). "Meeting of the Strategic Advisory Group of Experts on Immunization, September 2023: conclusions and recommendations". Weekly Epidemiological Record. 98 (47): 599–620. hdl:10665/374327.
World Health Organization (September 2018). "Dengue vaccine: WHO position paper – September 2018". Weekly Epidemiological Record. 93 (36): 457–76. hdl:10665/274316.
Redoni M, Yacoub S, Rivino L, Giacobbe DR, Luzzati R, Di Bella S (July 2020). "Dengue: Status of current and under-development vaccines". Reviews in Medical Virology. 30 (4): e2101. doi:10.1002/rmv.2101. hdl:1983/6d38d9b6-8e1b-4a84-85e3-edab4fc41957. PMID 32101634. S2CID 211536962.
World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

indiatimes.com

economictimes.indiatimes.com

"Panacea Biotec completes Phase I/II study of DengiAlI vaccine". India Times. 24 September 2020. Retrieved 26 October 2021.

medicines.org.uk

"Qdenga powder and solvent for solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 22 March 2023. Retrieved 9 April 2023.

medigen.com.tw

"MVC Obtains US NIH's Authorization to Develop Dengue Vaccine in 17 Countries". Medigen. 9 December 2016. Retrieved 26 October 2021.

merck.com

"Merck and Instituto Butantan Announce Collaboration Agreement to Develop Vaccines to Protect Against Dengue Infections". Merck. 12 December 2018. Retrieved 26 October 2021.

mercopress.com

en.mercopress.com

"Dengue vaccine available in Argentina". MercoPress. Retrieved 3 June 2024.
"Dengue vaccine available in Argentina". MercoPress. Retrieved 3 June 2024.

nih.gov

pubmed.ncbi.nlm.nih.gov

McArthur MA, Sztein MB, Edelman R (August 2013). "Dengue vaccines: recent developments, ongoing challenges and current candidates". Expert Review of Vaccines. 12 (8): 933–953. doi:10.1586/14760584.2013.815412. PMC 3773977. PMID 23984962.
Freedman DO (November 2023). "A new dengue vaccine (TAK-003) now WHO recommended in endemic areas; what about travellers?". J Travel Med. 30 (7): 1–3. doi:10.1093/jtm/taad132. PMID 37847608.
Redoni M, Yacoub S, Rivino L, Giacobbe DR, Luzzati R, Di Bella S (July 2020). "Dengue: Status of current and under-development vaccines". Reviews in Medical Virology. 30 (4): e2101. doi:10.1002/rmv.2101. hdl:1983/6d38d9b6-8e1b-4a84-85e3-edab4fc41957. PMID 32101634. S2CID 211536962.
Thisyakorn U, Thisyakorn C (January 2014). "Latest developments and future directions in dengue vaccines". Therapeutic Advances in Vaccines. 2 (1): 3–9. doi:10.1177/2051013613507862. PMC 3991153. PMID 24757522.
Yauch LE, Shresta S (2014). "Dengue virus vaccine development". Advances in Virus Research. 88: 315–372. doi:10.1016/B978-0-12-800098-4.00007-6. ISBN 9780128000984. PMID 24373316.
Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. (October 2014). "Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial". Lancet. 384 (9951): 1358–1365. doi:10.1016/s0140-6736(14)61060-6. PMID 25018116. S2CID 42841451.
Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al. (January 2015). "Efficacy of a tetravalent dengue vaccine in children in Latin America". The New England Journal of Medicine. 372 (2): 113–123. doi:10.1056/nejmoa1411037. PMID 25365753. S2CID 2839926.
Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. (September 2015). "Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease". The New England Journal of Medicine. 373 (13): 1195–1206. doi:10.1056/NEJMoa1506223. PMID 26214039.
Osorio JE, Huang CY, Kinney RM, Stinchcomb DT (September 2011). "Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever". Vaccine. 29 (42): 7251–7260. doi:10.1016/j.vaccine.2011.07.020. PMC 4592106. PMID 21777638.
Schwartz LM, Halloran ME, Durbin AP, Longini IM (June 2015). "The dengue vaccine pipeline: Implications for the future of dengue control". Vaccine. 33 (29): 3293–3298. doi:10.1016/j.vaccine.2015.05.010. PMC 4470297. PMID 25989449.
Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, et al. (November 2019). "Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents". The New England Journal of Medicine. 381 (21): 2009–2019. doi:10.1056/NEJMoa1903869. PMID 31693803. S2CID 207952783.
Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, et al. (March 2016). "The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model". Science Translational Medicine. 8 (330): 330ra36. doi:10.1126/scitranslmed.aaf1517. PMID 27089205. S2CID 206690615.
Whitehead SS (2016). "Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?". Expert Review of Vaccines. 15 (4): 509–517. doi:10.1586/14760584.2016.1115727. PMC 4956407. PMID 26559731.
Khetarpal N, Khanna I (2016). "Dengue Fever: Causes, Complications, and Vaccine Strategies". Journal of Immunology Research. 2016: 6803098. doi:10.1155/2016/6803098. PMC 4971387. PMID 27525287.
Manoff SB, Sausser M, Falk Russell A, Martin J, Radley D, Hyatt D, et al. (3 June 2019). "Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults". Human Vaccines & Immunotherapeutics. 15 (9): 2195–2204. doi:10.1080/21645515.2018.1546523. PMC 6773383. PMID 30427741.

ncbi.nlm.nih.gov

McArthur MA, Sztein MB, Edelman R (August 2013). "Dengue vaccines: recent developments, ongoing challenges and current candidates". Expert Review of Vaccines. 12 (8): 933–953. doi:10.1586/14760584.2013.815412. PMC 3773977. PMID 23984962.
Thisyakorn U, Thisyakorn C (January 2014). "Latest developments and future directions in dengue vaccines". Therapeutic Advances in Vaccines. 2 (1): 3–9. doi:10.1177/2051013613507862. PMC 3991153. PMID 24757522.
Osorio JE, Huang CY, Kinney RM, Stinchcomb DT (September 2011). "Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever". Vaccine. 29 (42): 7251–7260. doi:10.1016/j.vaccine.2011.07.020. PMC 4592106. PMID 21777638.
Schwartz LM, Halloran ME, Durbin AP, Longini IM (June 2015). "The dengue vaccine pipeline: Implications for the future of dengue control". Vaccine. 33 (29): 3293–3298. doi:10.1016/j.vaccine.2015.05.010. PMC 4470297. PMID 25989449.
Whitehead SS (2016). "Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?". Expert Review of Vaccines. 15 (4): 509–517. doi:10.1586/14760584.2016.1115727. PMC 4956407. PMID 26559731.
Khetarpal N, Khanna I (2016). "Dengue Fever: Causes, Complications, and Vaccine Strategies". Journal of Immunology Research. 2016: 6803098. doi:10.1155/2016/6803098. PMC 4971387. PMID 27525287.
Manoff SB, Sausser M, Falk Russell A, Martin J, Radley D, Hyatt D, et al. (3 June 2019). "Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults". Human Vaccines & Immunotherapeutics. 15 (9): 2195–2204. doi:10.1080/21645515.2018.1546523. PMC 6773383. PMID 30427741.

dailymed.nlm.nih.gov

"Dengvaxia- dengue tetravalent vaccine, live kit". DailyMed. 9 August 2019. Retrieved 17 May 2020.

nih.gov

"NIH-Developed Candidate Dengue Vaccine Shows Promise in Early-Stage Trial". National Institute of Allergy and Infectious Diseases. 23 January 2013. Retrieved 30 July 2015.

reuters.com

Vidalon D (4 October 2016). "Sanofi's dengue vaccine approved in 11 countries". Reuters. Retrieved 13 August 2017.
Steenhuysen J, Hirschler B (12 December 2017). "Did Sanofi, WHO ignore warning signals on dengue vaccine?". Reuters. Retrieved 13 December 2017.
Liu A (7 November 2017). "With interim phase 2 data, Takeda's dengue vaccine casts shadow on Sanofi". Reuters. Retrieved 18 February 2018.
"Takeda withdraws US application for dengue vaccine candidate". Reuters. 11 July 2023. Retrieved 3 October 2023.

sciencenewsline.com

"The Lancet: World's Most Advanced Dengue Vaccine Candidate Shows Promise in Phase 3 Trial". Science Newsline medicine. 10 July 2014. Archived from the original on 15 July 2014. Retrieved 13 July 2014.

scientificamerican.com

"Dengue Vaccine Maker Struggles to Find a Diagnostic That Will Make Its Product Safe to Use". Scientific American. 17 June 2018. Retrieved 20 September 2020.

semanticscholar.org

api.semanticscholar.org

Redoni M, Yacoub S, Rivino L, Giacobbe DR, Luzzati R, Di Bella S (July 2020). "Dengue: Status of current and under-development vaccines". Reviews in Medical Virology. 30 (4): e2101. doi:10.1002/rmv.2101. hdl:1983/6d38d9b6-8e1b-4a84-85e3-edab4fc41957. PMID 32101634. S2CID 211536962.
Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. (October 2014). "Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial". Lancet. 384 (9951): 1358–1365. doi:10.1016/s0140-6736(14)61060-6. PMID 25018116. S2CID 42841451.
Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al. (January 2015). "Efficacy of a tetravalent dengue vaccine in children in Latin America". The New England Journal of Medicine. 372 (2): 113–123. doi:10.1056/nejmoa1411037. PMID 25365753. S2CID 2839926.
Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, et al. (November 2019). "Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents". The New England Journal of Medicine. 381 (21): 2009–2019. doi:10.1056/NEJMoa1903869. PMID 31693803. S2CID 207952783.
Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, et al. (March 2016). "The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model". Science Translational Medicine. 8 (330): 330ra36. doi:10.1126/scitranslmed.aaf1517. PMID 27089205. S2CID 206690615.

statnews.com

"Caution on new dengue vaccine: In some countries, harm outweighs benefit". STAT. 1 September 2016. Retrieved 13 August 2017.

takeda.com

"Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries" (Press release). Takeda Pharmaceutical Company Limited. 25 March 2021. Retrieved 28 March 2021.
"Takeda's Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure" (Press release). Takeda. 22 August 2022. Retrieved 25 November 2022.
"Takeda's Dengue Vaccine Approved for Use in European Union". Takeda (Press release). 8 December 2022. Retrieved 10 February 2023.

tempo.co

en.tempo.co

"Dengue Fever Vaccine Available in Indonesia". 17 October 2016.

tga.gov.au

"Dengvaxia dengue tetravalent vaccine (live, attenuated), powder and diluent for suspension for injection (275964)". Therapeutic Goods Administration (TGA). 26 May 2022. Retrieved 9 April 2023.
"Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.

uftm.edu.br

bdtd.uftm.edu.br

Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. (September 2015). "Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease". The New England Journal of Medicine. 373 (13): 1195–1206. doi:10.1056/NEJMoa1506223. PMID 26214039.

umn.edu

cidrap.umn.edu

"Sanofi restricts dengue vaccine but downplays antibody enhancement". CIDRAP. 1 December 2017. Retrieved 20 September 2020.
"Sanofi restricts dengue vaccine but downplays antibody enhancement". CIDRAP. December 2017. Retrieved 2 December 2017.

web.archive.org

"Dengvaxia EPAR". European Medicines Agency (EMA). 23 October 2019. Archived from the original on 6 December 2019. Retrieved 6 December 2019.
"First FDA-approved vaccine for the prevention of dengue disease in endemic regions". U.S. Food and Drug Administration (FDA) (Press release). 1 May 2019. Archived from the original on 6 December 2019. Retrieved 14 November 2019. This article incorporates text from this source, which is in the public domain.
"Dengvaxia". U.S. Food and Drug Administration (FDA). 21 May 2019. STN 125682. Archived from the original on 6 December 2019. Retrieved 6 December 2019. This article incorporates text from this source, which is in the public domain.
Palmer, Eric (9 December 2015). "Sanofi gets first approval for long-anticipated vaccine against dengue fever". FiercePharma. Archived from the original on 16 March 2016. Retrieved 10 December 2015.
"Qdenga: Pending EC decision". European Medicines Agency (EMA). 14 October 2022. Archived from the original on 14 October 2022. Retrieved 14 October 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Vaccine Development. Dengue Vaccine Initiative". Archived from the original on 21 August 2019. Retrieved 31 July 2015.
Roehrig JT (April 2013). "Current Status of Dengue Vaccine Development" (PDF). Archived from the original (PDF) on 11 December 2015. Retrieved 31 July 2015.

who.int

"Vaccines and immunization: Dengue". World Health Organization (WHO). Retrieved 5 October 2021.
Roehrig JT (April 2013). "Current Status of Dengue Vaccine Development" (PDF). Archived from the original (PDF) on 11 December 2015. Retrieved 31 July 2015.